Related Experiment Video
Updated: Mar 2, 2026
10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
3.5K
Does infection by the hepatitis C virus decrease the response of immunization against the hepatitis B virus in
Tarcila Maria Bonfim Ferreira1, Tácio Giordano Santana Guimarães2, Andrea Martins Melo Fontenele2
1Universitário Presidente Dutra.
Jornal Brasileiro De Nefrologia
|May 11, 2017
Summary
Hepatitis B Virus (HBV) vaccination response is lower in chronic kidney disease (CKD) patients undergoing dialysis. Lack of Hepatitis C Virus (HCV) infection is linked to successful HBV vaccine response in these high-risk patients.
Area of Science:
- Nephrology
- Immunology
- Virology
Background:
- Hepatitis B Virus (HBV) vaccination is crucial for preventing transmission.
- Patients with chronic kidney disease (CKD) on dialysis face higher HBV infection risk and poorer vaccine response.
- Uremia in CKD patients may impair immune response to vaccinations.
Purpose of the Study:
- To assess Hepatitis B Virus (HBV) vaccine effectiveness in hemodialysis patients.
- To identify factors influencing HBV vaccine response in CKD patients.
- To evaluate seroconversion rates and associated clinical variables.
Main Methods:
- Assessed hemodialysis patients with HBsAG and negative anti-HBC.
- Administered a full HBV vaccination schedule.
- Utilized logistic regression to analyze factors like age, diabetes, dialysis duration, and Hepatitis C Virus (HCV) status.
Main Results:
- Achieved a 70% vaccine response rate (seroconversion) to HBV in the CKD dialysis cohort.
- Lack of anti-HCV infection was significantly associated with successful anti-HBs seroconversion (p=0.021).
- Identified potential protective effect of HCV infection on HBV vaccine response.
Conclusions:
- The HBV vaccine response rate in dialysis patients with CKD is 70%.
- Hepatitis C Virus (HCV) infection may be associated with a decreased response to the HBV vaccine in CKD dialysis patients.
- Further research is needed to elucidate the interaction between HCV and HBV vaccine response in CKD.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
01:24Hemodialysis II: Procedure and Complications
1.3K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.3K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
317
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
317
01:29Pulmonary Tuberculosis I
1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
268
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
268